

# Jay C Groppe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7687783/publications.pdf>

Version: 2024-02-01

10  
papers

1,182  
citations

1040056

9  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1319  
citing authors

#	ARTICLE	IF	CITATIONS
1	Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. <i>Human Mutation</i> , 2009, 30, 379-390.	2.5	364
2	The BMP7/ActRII Extracellular Domain Complex Provides New Insights into the Cooperative Nature of Receptor Assembly. <i>Molecular Cell</i> , 2003, 11, 605-617.	9.7	248
3	Cooperative Assembly of TGF- $\beta$ Superfamily Signaling Complexes Is Mediated by Two Disparate Mechanisms and Distinct Modes of Receptor Binding. <i>Molecular Cell</i> , 2008, 29, 157-168.	9.7	247
4	Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1652-1665.	2.8	110
5	Functional Modeling of the ACVR1 (R206H) Mutation in FOP. <i>Clinical Orthopaedics and Related Research</i> , 2007, 462, 87-92.	1.5	86
6	In vitro Analyses of the Dysregulated R206H ALK2 Kinase-FKBP12 Interaction Associated with Heterotopic Ossification in FOP. <i>Cells Tissues Organs</i> , 2011, 194, 291-295.	2.3	65
7	Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva ( <i>ACVR1</i> ) Tj ETQq1 1 0.784314 rgBT /Overl 2265-2271.	1.2	33
8	Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 1237-1253.	5.0	16
9	Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification. <i>Bone</i> , 2018, 112, 71-89.	2.9	10
10	An ACVR1 R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva. <i>American Journal of Medical Genetics, Part A</i> , 2021, , .	1.2	3